Skip to main content
. Author manuscript; available in PMC: 2011 May 3.
Published in final edited form as: Clin Cancer Res. 2008 Jun 1;14(11):3327–3337. doi: 10.1158/1078-0432.CCR-07-4495

Fig. 1.

Fig. 1

RT-PCR analysis of HMGA2 and PLAG1 in thyroid tumors. The mRNA expression of both HMGA2 and PLAG1 in malignant [A, papillary thyroid carcinoma (PTC; n = 10) and follicular variant of papillary thyroid carcinoma (FVPTC; n = 7)] and benign [B, follicular adenoma (FA; n = 11) and adenomatoid nodule (AN; n = 10)] was determined by RT-PCR. GAPDH expression after 22 PCR cycles and 35 PCR cycles served as a loading control for malignant and benign tumors, respectively. Note: with the exception of one adenomatoid nodule (AN4) the benign tumors exhibited no detectable levels of HMGA2 or PLAG1. Only a smear was found after extending the PCR cycles to 40.